Janus Henderson Group plc (NYSE: JHG) — The Activist Finally Rang the Register: A Structurally-Challenged Active Manager Sold Whole at $52 Cash

Independent equity analysis. As-of date: July 11, 2026. Fiscal year ends December 31.

⚡ The Author’s Take

This is the author’s own independent opinion and general information, not investment advice. The analysis that follows deliberately carries no position and no price target.

Verdict: THE TRADE IS OVER — NO LIVE POSITION. Janus Henderson was taken private and delisted on June 30, 2026 at $52.00/share cash. Public shareholders were cashed out; there is nothing left to buy or sell. Retrospective judgment: $52 was a full-to-generous exit for public holders (a 25% premium to the undisturbed ~$41.60) and a reasonable-but-not-cheap entry for the Trian/General Catalyst/QIA consortium — ~11x FY25 adjusted EPS (~12–13x on the normalized low-$4s run-rate), ~6–7x EV/EBITDA, ~1.6% of AUM. If a comparable public active manager traded at JHG’s fundamentals today, my call would be HOLD/AVOID-here. Conviction on the fairness read: medium-high.

Janus Henderson is the clearest case study of the decade in what happens to a subscale, structurally-challenged traditional active manager: after five years, its largest shareholder — Nelson Peltz’s Trian, a 20.6% holder and board presence since 2020–2022 — concluded that the surest way to realize value was not standalone compounding but selling the entire company for cash to a private consortium (Trian rolling its stake, alongside General Catalyst, the Qatar Investment Authority, Sun Hung Kai and Lunate). That is the tell. The “turnaround” the sell-side celebrated — six straight quarters of net inflows, record ~$493B AUM, adjusted EPS up sharply — is real at the headline but hollow underneath: the flow recovery is almost entirely one $46.5B low-fee Guardian insurance mandate plus market beta; the high-fee active-equity core is in accelerating outflow (−$14B in 2025); the blended fee rate is compressing (48.9→45.2 bps); and FY2025’s earnings jump is flattered by a lumpy ~$423M hedge-fund performance-fee crystallization that is not run-rate. The genuine bright spots — a first-mover active-ETF franchise led by the JAAA CLO ETF (~$25B, ~3x its nearest rival) and a credible private-credit/insurance build-out — are exactly the assets a control buyer wants to fund privately, away from quarterly-flow scrutiny.

So why “full-to-generous” rather than “steal”? Because $52 was struck at JHG’s richest-ever price-to-book (~1.51x stated, 98th own-history percentile) into a hot AM tape where the whole group (BEN, AB, AMG) re-rated to decade-high multiples — and against a business whose normalized ROE is mid-teens, whose moat is narrow (distribution shelf + product first-mover, no structural barrier against passive), and whose core engine is still melting. The consortium is paying a market-clearing price for optionality on the private-markets/ETF pivot and ~$0.9B of net cash and ~$0.7B/yr of free cash flow it can lever (financing was committed by JPMorgan, Citi, BofA, Jefferies and MUFG). Catchy tag: the activist didn’t fix it — he sold it. What would have flipped the fairness read to “cheap for the buyers”: evidence the active-equity core had genuinely stabilized on an organic, ex-Guardian, ex-lumpy-perf-fee basis before the bid. What confirms “full for sellers”: the core kept bleeding right through the deal, and the premium was paid on a peak multiple in a peak tape. This memo is a completed-deal post-mortem — the framework below describes the asset the buyers now own and asks whether the price was right; it takes no position because there is no longer a security to take one in.

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are FACT; attributed causes are INTERPRETATION.

Over the trailing ~60 months JHG round-tripped from the post-merger optimism of 2021 to a deep 2022 bear-market low, then ground higher on the Dibadj turnaround and — decisively — was re-priced to, and pinned at, a cash take-private level. The stock bottomed at a ~$16.87 close (Oct 11, 2022) — the five-year low — and reached a five-year/52-week high of $53.21 (Feb 26, 2026) as the deal was struck; its final trade was $51.95 on June 30, 2026, the day it delisted at $52.00 cash. The 52-week range was roughly $39.80–$53.21. Unlike a normal tape, the last seven months are not a fundamental signal — they are merger arithmetic.

Cycle narrative. (1) 2021 rode the reflation rally and optimism that the 2017 Janus Capital (Denver) + Henderson (UK) merger would finally deliver synergies; Trian had already disclosed a stake in October 2020 and begun pressing for change. (2) 2022’s rate shock hit every asset manager at once — equities and bonds fell together, the AUM-linked fee base contracted, and JHG more than halved to a $16.9 low. (3–4) Through 2023–2024 the stock nearly tripled off the low as new CEO Ali Dibadj’s “protect & grow / amplify / diversify” agenda took hold, markets recovered, flows stopped deteriorating and then turned positive, and the active-ETF and private-credit pivots gained visible traction. (5) The April-2025 tariff crash briefly knocked the high-beta name back to ~$35. (6) It recovered as the Guardian Life insurance mandate (+$46.5B) landed and management booked a sixth consecutive positive-flow quarter on record AUM. (7) The defining event came in late October 2025, when Trian (20.6%) and General Catalyst submitted a nonbinding proposal to take the company private; a special committee negotiated a definitive $49.00 deal (Dec 22, 2025, an 18% premium to the undisturbed ~$41.60), subsequently raised to $52.00 (a 25% premium). (8) From January 2026 the stock traded as pure merger-arb around $52 — 99.7% shareholder approval on April 16, regulatory and client consents on June 18, and completion and NYSE delisting on June 30, 2026 at $52.00 cash. (The June-2026 removal from the S&P MidCap 400 was the mechanical index deletion on delisting — not an S&P 500 promotion.)

1. Executive Summary

Janus Henderson Group was, until June 30, 2026, one of the larger publicly-traded independent global active asset managers — the product of the 2017 merger of Janus Capital Group (Denver) and Henderson Group (London). It managed ~$493 billion of AUM at year-end 2025 (~$480B at March 31, 2026) across equities, fixed income, multi-asset and a growing alternatives/private-markets book, earning a management fee measured in basis points of AUM plus performance fees. FY2025 revenue was ~$3.10 billion and adjusted diluted EPS was ~$4.78 on an adjusted operating margin of 36.0%. On June 30, 2026 the company was taken private for $52.00/share in cash (~$7.4 billion of equity value) and delisted from the NYSE. The acquiring consortium was led by Trian Fund Management (Nelson Peltz), a 20.6% shareholder and board presence that rolled its stake, together with General Catalyst, the Qatar Investment Authority, Sun Hung Kai & Co. and Lunate; CEO Ali Dibadj and the management team continue, with the firm keeping its London and Denver bases. This memo is therefore a completed-transaction post-mortem: there is no live public security, no position to take, and no price target — the analytical question is whether $52.00 was a fair clearing price, and what the sale says about the economics of subscale active management.

The single most important fact about the “turnaround” is that it was largely optical. Net long-term flows swung from roughly −$0.7B (2023) to +$2.4B (2024) to +$56.5B (2025) — a headline that reads like a franchise inflection and produced six consecutive positive-flow quarters, the first sustained run since the 2017 merger. But the composition is unflattering: the 2025 surge is almost entirely a single ~$46.5B low-fee Guardian Life general-account fixed-income mandate plus positive markets — strip Guardian out and organic long-term flows were only ~+$10B (~2–3% organic), and the high-fee active-equity core — the heart of the business — was in accelerating net outflow: −$2.2B → −$6.5B → −$14.0B. AUM grew 30% in 2025, but that decomposed to Guardian (+$46.5B), market appreciation (+$49.7B) and FX (+$8.3B) — very little high-quality organic active growth. Meanwhile the blended net management-fee rate compressed from 48.9 to 45.2 bps (fixed income fell to ~19.8 bps under the Guardian drag), the textbook mix-shift squeeze on a traditional manager.

The earnings are similarly flattered. FY2025 GAAP diluted EPS of ~$5.34 (and adjusted ~$4.78) jumped on a lumpy ~$423 million hedge-fund performance-fee crystallization (total performance fees leapt from ~$70M in 2024 to ~$460M in 2025) plus favorable one-time items — none of it run-rate. On a normalized basis (stripping the lumpy performance fee), adjusted EPS was closer to ~$3.8–4.1, and the ~53% reported ROE normalizes to the mid-teens — respectable for an asset-light model but hardly the compounding machine the multiple implied. The business does have genuine, durable positives: a net-cash balance sheet (~$2.8B cash & investments vs. ~$0.5B debt; ~$0.9B net cash), ~$0.7B/year of free cash flow on negligible capex, a first-mover active-ETF franchise (JAAA, the pioneer AAA-CLO ETF, ~$25B and ~3x its nearest competitor; JHG is a top-3 active fixed-income ETF issuer), strong fixed-income/multi-asset/alternatives investment performance, and a credible private-credit/insurance diversification (Guardian, VPC, NBK, Rantum, RBA). These are precisely the assets a private control buyer wants to fund and lever outside the glare of public flow reporting.

The valuation verdict on the deal: $52.00 was a market-clearing, full price for public sellers and a reasonable-not-cheap entry for the buyers. It equated to ~11x FY25 adjusted EPS of $4.78 (~12–13x on the normalized low-$4s), ~6–7x EV/EBITDA, ~1.6% of AUM and a ~3% (now-suspended) dividend yield — struck at JHG’s richest-ever price-to-book (~1.51x, 98th own-history percentile) into an AM tape where BEN, AllianceBernstein and AMG had all re-rated to decade-high multiples. The 25% premium fairly compensated public holders for a business whose structural trajectory (fee compression + active-equity outflows + no barrier against passive) is negative; the consortium is underwriting the private-markets/ETF optionality, the net cash and the free cash flow, and betting it can build “the most technologically sophisticated asset manager in the world” away from quarterly scrutiny. This memo lays out the franchise, the mechanism, the numbers and the deal economics, and leaves the fairness judgment to the reader (the labeled exception is the author’s opinion above).

2. Business Overview

2.1 What Janus Henderson sold, and how it made money

Janus Henderson is an active asset manager. Through a single global operating platform (unlike the multi-boutique federations of Franklin or AMG) it manages equity, fixed-income, multi-asset and alternative strategies for intermediary (retail/advisor), institutional and self-directed clients across North America (~67% of client AUM), EMEA/LatAm (~25%) and Asia-Pacific (~8%), and earns a management fee expressed in basis points of assets under management, supplemented by performance fees on certain strategies. The revenue model is high-quality in the abstract — recurring, contractual, asset-light, negligible tangible capital, ~$0.7B of annual free cash flow on ~$10–18M of capex — but it carries the two structural vulnerabilities that govern the entire analysis: (1) revenue = assets × fee rate, and both are under secular pressure — assets from the migration out of active mutual funds into passive, the fee rate from mix toward lower-fee vehicles and mandates; and (2) revenue is market-sensitive — fees accrue on daily asset values, so a rising market mechanically lifts revenue and a drawdown cuts it regardless of the firm’s own execution. JHG’s equity beta of ~1.3 is the direct expression of that sensitivity.

FY2025 total revenue of ~$3.10B comprised management fees (the large majority), performance fees (~$460M in 2025, but see the lumpiness caveat below), and shareowner-servicing and other fees. On the company’s adjusted presentation — which strips distribution pass-throughs and acquisition/consolidation noise — the reported adjusted operating margin was 36.0% in FY2025, up sharply from the mid-20s%/low-30s% earlier in the cycle, though that improvement is itself partly performance-fee-driven.

2.2 Assets under management — the scoreboard

For an active manager, AUM and net flows are the business. JHG’s year-end AUM progression captures both the market cycle and the flow story:

The 2022 collapse (~$432B → ~$287B) was the bear market compounding chronic active-equity outflows. The recovery to a record ~$493B in 2025 looks like vindication — but as detailed below, ~$46.5B of the 2025 increase was the one-off Guardian mandate, ~$49.7B was market appreciation, and ~$8.3B was FX, leaving only modest high-quality organic growth. The record AUM is real; its quality is not what the flow headline implies.

2.3 Asset-class and channel mix

By capability, JHG remained equity-heavy (its historical franchise and its highest-fee book, ~53–54 bps) with a large and now faster-growing fixed-income business (~20–26 bps, dragged down by low-fee Guardian assets), a multi-asset book, and a small but strategically emphasized alternatives/private-markets segment (~82 bps — the highest-fee category and the focus of the diversification push). The intermediary channel is the largest and the one management most prizes (U.S. intermediary posted nine consecutive positive-flow quarters into Q3’25). The strategic problem is stark and simple: the highest-fee capability (active equities) is the one losing assets, and the fastest-growing (fixed income via Guardian) is the lowest-fee. That is fee-rate compression by construction.

2.4 The 2017 merger and the single-platform model

JHG’s structure is a legacy of the May 2017 merger of equals between Janus Capital Group (Denver; U.S. equities, global-macro fixed income, the INTECH quant unit) and Henderson Group (London; European/global equities, credit, investment trusts). The deal was sold on cost synergies and distribution complementarity (Janus strong in the U.S. and Japan via its Dai-ichi Life relationship; Henderson strong in the U.K., Europe and Australia). In practice the first five years disappointed: persistent net outflows in most quarters between 2017 and 2023, the wind-down of INTECH, star-manager departures, and a share price that went nowhere — precisely the backdrop that drew Trian’s October-2020 activist stake. Unlike Franklin’s multi-boutique federation or AMG’s affiliate-equity model, JHG runs a single integrated operating platform with one P&L, one distribution organization and one brand architecture — which lowers cost duplication and simplifies the story, but also means there is nowhere to hide a weak franchise: the melting active-equity book sits on the same platform as the growing ETF book, and the blended fee rate reflects the whole.

2.5 The revenue line, decomposed

FY2025 revenue of ~$3.10B is best understood net of two distortions. Management fees — the recurring core — scale with average AUM and the blended fee rate; on ~$430B average AUM at ~45 bps that is roughly ~$1.9–2.0B of net management fees, the durable engine. Performance fees contributed an anomalous ~$460M in 2025 (versus ~$70M in 2024 and ~$5M in 2023), ~$423M of it a single lumpy hedge-fund crystallization — the line that must be normalized away before any run-rate or valuation conclusion. Shareowner-servicing and other fees are largely pass-through, and the consolidation of Victory Park Capital grosses up both investment revenue and expense with a large offsetting non-controlling interest. Read correctly — net management fees plus a normalized performance-fee contribution, net of NCI — the underlying revenue trajectory is a steady, market-and-mix-driven grind, not the +25% growth the headline implies.

3. Industry Dynamics

Verdict up front: a structurally unattractive core industry in secular decline, with pockets of defensible growth (active ETFs, private credit, insurance solutions) into which JHG was rationally pivoting.

Traditional active asset management is one of the clearest capital-cycle-in-reverse stories in public markets (Marathon lens): for two decades, capital and client assets have exited active management in favor of passive/index products that deliver market returns at a fraction of the fee. The economics are brutal and one-directional: passive charges ~3–10 bps versus ~45–90 bps for active; the majority of active managers underperform their benchmarks net of fees over 5–10 years; and the flow of new savings (especially in the U.S. via advisor model portfolios and target-date funds) defaults to passive. The result is relentless fee compression and organic asset attrition for the incumbent active complex — a shrinking profit pool that consolidation (the supply-side response) only partly offsets.

Within that decline, three surviving niches carry better economics, and JHG oriented its strategy around all three:

• Active ETFs — the fastest-growing wrapper in asset management, where active managers can recapture flows lost to passive by delivering active strategies in the tax-efficient, liquid, advisor-preferred ETF format. JHG’s early, scaled position here (JAAA and the active fixed-income ETF suite) is its single best structural asset.
• Private credit / alternatives — higher-fee, stickier, capacity-constrained capital that is genuinely growing as banks retrench from lending. JHG’s VPC, NBK, Rantum and RBA acquisitions target this.
• Insurance / general-account solutions — very long-duration, low-churn (if low-fee) mandates; the Guardian relationship (~$45–50B, ~10% of AUM including CNO) anchors this.

Quantifying the tide. The scale of the secular shift is not subtle. U.S. passive equity funds surpassed active funds in assets in 2019 and have kept gaining share every year since; index and ETF vehicles now capture the large majority of net new flows into U.S. long-term funds, while active mutual funds have seen cumulative net redemptions running into the trillions of dollars over the past decade. Asset-weighted average fees across the fund industry have fallen by roughly half over fifteen years. For an incumbent active manager this shows up as the exact pattern JHG exhibits: negative organic growth in the legacy book, a declining blended fee rate, and earnings that depend on rising markets to offset unit attrition. The Marathon capital-cycle framing is instructive but two-edged: capital is exiting active management (industry consolidation, fee wars, and headcount cuts are the supply-side response, which should eventually stabilize economics for the surviving few), but the demand for the product is migrating structurally to passive and to private markets — so the classic capital-cycle “high returns mean-revert down, low returns mean-revert up” does not cleanly apply, because the low returns here are driven by a permanent substitution, not a temporary capacity glut. JHG’s pivot into ETFs (recapturing passive-adjacent flows) and private credit (a genuinely capacity-constrained, higher-return sub-pool where banks are retreating) is the rational way to fish where the water is rising rather than draining.

Sizing the surviving sub-pools. Active ETFs, though still a minority of total ETF assets, have been the fastest-growing wrapper in the industry, compounding at well over 30% annually as issuers convert strategies and advisors adopt the format; private credit has grown into a multi-trillion-dollar asset class as direct lending fills the gap left by bank retrenchment; and insurance general-account outsourcing is a large, sticky, if low-fee, pool. JHG is a credible-but-subscale participant in all three — meaningful in active fixed-income ETFs (via JAAA), early in private credit (VPC/NBK/Rantum), and anchored in insurance (Guardian/CNO). None of these is yet large enough to offset the legacy melt on its own, which is the crux of the growth debate.

Barriers to entry (Greenwald lens) are modest. There is some customer captivity — distribution-shelf real estate, advisor and platform inertia, the operational friction of moving institutional mandates, and the stickiness of insurance general-account and ETF assets — and some economies of scale in distribution, compliance and technology. But there is no durable barrier against the passive alternative, switching costs for performance-chasing retail flows are low, and investment performance (the notional product differentiator) is not reliably persistent. This is a narrow-moat-to-no-moat industry for a subscale participant, which is precisely why the rational endgame for JHG was consolidation — and ultimately a whole-company sale.

4. Competitive Position

Verdict: a mid-scale generalist with a narrow, product-specific edge (active-ETF/CLO first-mover scale, strong FI/multi-asset/alts performance, an insurance anchor) but no wide moat — a price-taker in a fee-compressing industry, structurally subscale versus the passive giants.

At ~$490B of AUM, JHG was a mid-tier manager: an order of magnitude smaller than BlackRock (~$11–12T), Vanguard, Fidelity, State Street, Amundi or Capital Group, and roughly a peer to Invesco (IVZ), AllianceBernstein (AB), Franklin (BEN) and AMG-affiliated boutiques in the crowded ~$0.5–1.5T active middle. In an industry where scale drives the ability to absorb fee compression, invest in technology and distribution, and cross-subsidize product build-out, subscale is a genuine competitive disadvantage — one that the take-private explicitly aims to solve with patient private capital and AI investment.

Where JHG genuinely differentiated:

• Active-ETF / CLO first-mover scale. JHG created and scaled JAAA, the pioneering AAA-CLO ETF, to ~$25B (~3x its nearest CLO-ETF rival) and built the 3rd-largest active fixed-income ETF and 8th-largest active-ETF franchise overall. First-mover scale in a fast-growing wrapper is a real, if narrow and low-fee, advantage.
• Fixed income, multi-asset and alternatives investment performance. As of 12/31/25, 68/93/90/92% of fixed-income AUM beat benchmark over 1/3/5/10 years; multi-asset 96/96/98/97%; alternatives ~100%. These are strong, marketable records.
• The Guardian anchor and the growing insurance/private-credit platform provide long-duration, sticky capital and a differentiated origination story.

Where it did not:

• The active-equity core — its highest-fee, most-visible book — underperforms and is bleeding assets. Only 55/46/48/54% of equity AUM beat benchmark over 1/3/5/10 years (roughly a coin flip over 3–5 years), and net equity outflows accelerated to −$14B in 2025. A generalist active-equity brand with mediocre performance has no pricing power against passive.
• Scale, cost position and brand are not sources of durable advantage at JHG’s size. The “moat,” to the extent it exists, is distribution real estate and product first-mover status — not a structural cost or network barrier that would let economics improve with scale in the way a genuine moat requires.

Peer-by-peer. Against T. Rowe Price, JHG is the weaker franchise: TROW carries a fortress net-cash balance sheet, a higher and cleaner ROE, a 40-year dividend-growth record and a stronger (if also passive-pressured) retirement/target-date moat — and trades at a similar adjusted multiple without needing a buyout to realize value. Against Franklin (BEN), JHG is cleaner and less levered — Franklin’s book is stuffed with ~$10B of Legg Mason/Putnam goodwill, its Western Asset unit suffered a scandal-driven ~$140B outflow, and its share count rose on stock-funded M&A; JHG’s steady buyback and single-platform simplicity compare favorably. Against AllianceBernstein (AB), JHG lacks AB’s Equitable insurance parent and Bernstein research franchise but avoids the Up-C/MLP structural complexity. Against Invesco (IVZ), JHG has stronger recent flow momentum and a cleaner balance sheet. The common thread across the entire peer set is that none has a wide moat and all are fighting the same passive tide — which is why the whole group re-rated together in 2025–26 on the “flows are turning / rates are falling” narrative, and why a subscale member being taken private is a coherent sector signal rather than an idiosyncratic event.

Net: a competent, improving, well-run mid-cap manager with a couple of genuinely good product franchises — but not a business whose competitive position would protect returns on capital against the secular tide without continual reinvention. The sale to a private consortium is the market’s verdict on that reality.

5. Growth History and Forward Opportunities

Verdict: LOW-to-MIXED-quality growth. The 2025 headline inflection was driven by one low-fee insurance mandate, market beta, FX and M&A — not by durable organic active growth; the only clean organic engine is the active-ETF franchise.

The flow record is the crux of the entire thesis, so it deserves precision. Net long-term flows ran −$0.7B (2023) → +$2.4B (2024) → +$56.5B (2025), producing six straight positive quarters — management’s headline proof of a franchise turn. Decomposed, that story weakens considerably:

• Guardian is the story. The ~$46.5B Guardian general-account mandate (recognized largely in Q2’25) accounts for the overwhelming majority of 2025’s positive flows. It is low-fee (dragging the FI fee rate to ~19.8 bps), non-repeatable, and single-client — valuable long-duration capital, but not evidence of broad franchise health.
• Ex-Guardian organic flows were only ~+$10B (~2–3% organic) — positive, and better than the years of outflows, but hardly the inflection the multiple came to imply.
• The high-fee active-equity core is in accelerating outflow: −$2.2B → −$6.5B → −$14.0B. This is the single most important negative fact in the growth section: the part of the business that actually earns the fees is shrinking faster, not stabilizing.
• AUM growth in 2025 (+30%) was ~40% Guardian, ~42% market appreciation, ~7% FX — i.e., mostly beta and a one-off, with modest organic contribution.
• The flow cadence corroborates the caveat. The six-quarter positive streak leaned heavily on the Q2’25 Guardian recognition (a ~$46B quarter), with the surrounding quarters running at low-single-digit-billion organic rates (Q1’25 ~+$2B, Q3’25 ~+$7B including a strong +$5.1B intermediary contribution at a 9% organic rate). A 7% firm-wide organic growth rate in Q3’25 is genuinely good — but management itself guided that this level would not repeat in Q4, underscoring that the run-rate organic growth is positive-but-modest, not the double-digit inflection the multiple flirted with. The breadth improved (21 strategies with >$100M of quarterly inflows versus 11 a year earlier, spanning ETFs, equities, fixed income, absolute return and alternatives), which is a real quality signal; but breadth in the growing categories does not change the arithmetic that the large, high-fee equity book is still the dominant drag.

Forward opportunities (all now to be pursued privately):

• Active ETFs — the genuine organic engine. JAAA (~$25B) and the broader active-FI ETF suite (JMBS, JSI, JBBB, VNLA, plus new launches like JABS) were compounding rapidly; extending the model into active equity and multi-asset ETFs and into Europe (via Tabula) is the clearest growth vector.
• Private markets / private credit — VPC (asset-backed/opportunistic credit), NBK (EM private credit), Rantum (DACH private debt/PE), Privacore (retail alternatives distribution) build a higher-fee, stickier book from a small base.
• Insurance solutions — leveraging Guardian/CNO into further general-account and insurance-linked mandates.
• AI / technology — the consortium’s stated ambition to make JHG “the most technologically sophisticated asset manager in the world” is the private-ownership thesis for operating-leverage and distribution gains.

The honest read: JHG’s forward growth is real but niche and reinvention-dependent — it requires continually out-building the secular decline of the legacy active-equity core. That is a viable private-equity project; it was a hard public-market compounding story, which is why the multiple never fully believed it until a cash bid arrived.

6. Financial Quality

Verdict: high-quality cash economics (asset-light, net cash, strong FCF) wrapped around low-quality, flattered reported earnings — FY2025’s profit spike is substantially one-time.

Revenue and the 2025 gross-up. Revenue rose from ~$2.47B (2024) to ~$3.10B (2025), +25%. Part is genuine (higher average AUM on strong markets and the Guardian assets), but two distortions inflate the optics: (a) the ~$423M lumpy hedge-fund performance-fee crystallization (total performance fees ~$70M → ~$460M) — a non-recurring windfall; and (b) the consolidation of Victory Park Capital (55%-owned) grosses up both revenue and expense with a large offsetting non-controlling interest (minority interest on the balance sheet jumped from ~$492M to ~$1,012M), so a chunk of the revenue growth does not accrue to JHG shareholders. Normalizing for both, underlying fee-revenue growth was solid-but-unspectacular and consistent with AUM/markets.

Margins. Adjusted operating margin of 36.0% (FY2025) is genuinely strong for the sector and up markedly from the low-20s%/low-30s% earlier in the cycle — but it is partly a performance-fee artifact; the underlying, ex-lumpy-fee margin is lower (low-30s%). The trajectory is nonetheless favorable: Dibadj’s cost discipline plus operating leverage on rising AUM did expand the underlying margin.

Earnings quality — a revealing inversion. Adjusted diluted EPS ran $2.63 (2023) → $3.53 (2024) → $4.78 (2025), while GAAP diluted EPS ran $2.44 → $2.62 → $5.34. The tell is the 2025 crossover: in 2023–24, GAAP was below adjusted (the normal intangible-amortization add-back); in 2025, GAAP exceeds adjusted because ~$183M of “extraordinary items net of tax” plus a ~$193M favorable other-non-operating swing — seed/consolidated-investment-product gains in a strong tape and VPC-related fair-value marks — flowed through GAAP but are non-recurring and/or offset in non-controlling interest. So the ~9.7x “GAAP P/E” optic is flattered garbage; the right earnings base is adjusted ~$4.78 — and even that is helped by an elevated Q4’25 ($2.01 adjusted) on lumpy performance fees, so the true run-rate is in the low-$4s. This is the single most important quality-of-earnings caveat: the deal multiple looks cheap (~11x) on the flattered number and fair (~12–13x) on the normalized one.

Returns on capital. Reported ROE of ~53% (2025) is not a real economic return — it is flattered by the one-time earnings over a thin, buyback-shrunk equity base, and JHG’s equity is stuffed with ~$4.15B of goodwill and intangibles (largely the 2017 merger and subsequent deals) against ~$5.1B of common equity, leaving tangible common equity of only ~$0.96B. Normalized ROE on adjusted earnings is ~14–15%, and ROIC of ~12.6% (2025) sits modestly above a ~9–10% cost of equity — a decent asset-light return, above cost of capital but hardly exceptional for a manager fighting secular fee/outflow pressure, and far from the reported headline. The intangible-heavy book is why the “richest-ever 1.51x P/B” is both true and somewhat misleading: on tangible book the multiple is ~8x, on earnings/AUM it is unremarkable.

The multi-year fee and margin walk. The through-cycle numbers frame both the challenge and the operating leverage. Revenue ran ~$2.77B (2021) → ~$2.20B (2022) → ~$2.10B (2023, the trough) → ~$2.47B (2024) → ~$3.10B (2025); GAAP operating margin swung from ~34% (2021) to ~23% (2023 trough) back to ~32% (2025), and adjusted operating margin held a 33–38% band, reaching 36.0% in 2025. The message is that JHG has real operating leverage on a market recovery — incremental/flow-through margins ran ~54% in 2025 — but that leverage is cyclical and symmetric: the same fee base that expands the margin on rising AUM contracts it in a drawdown, as 2022–23 demonstrated (revenue −24% peak-to-trough). The adjusted margin’s improvement under Dibadj is partly genuine cost discipline (headcount, real-estate and platform rationalization) and partly the beta of a strong tape plus the performance-fee windfall — disentangling the two is why the normalized margin (low-30s%) matters more than the 36.0% headline.

The consolidated-investment-products (CIP/VIE) mechanics. A recurring source of noise is JHG’s consolidation of seeded investment products and — since October 2024 — the majority-owned Victory Park Capital funds and CLOs as variable-interest entities. This inflates gross assets, gross revenue, gross expense and, most visibly, non-controlling interest (which jumped from ~$492M to ~$1,012M in 2025) — but the overwhelming majority of that NCI is third-party fund capital, not JHG economics (VPC’s own redeemable NCI was only ~$32M). The correct read strips the CIP/VIE gross-up and values JHG on its net-of-NCI, adjusted economics; the screen-based gross figures materially overstate the business’s size and can make growth look stronger and returns look noisier than they are.

Balance sheet — a genuine fortress. This is the cleanest positive in the financials. At year-end 2025: ~$2.83B of cash and investments (cash ~$1.29B plus ~$1.53B of seed/other investments) against ~$0.50B of total debt, i.e. ~$0.9B of net cash (more on a cash-plus-investments basis). Debt is minimal and was termed out on favorable terms; there are no pension or off-balance-sheet liabilities of note. Free cash flow of ~$0.71B (2025), ~$0.68B (2024), ~$0.43B (2023) and ~$0.89B (2021) comfortably covered the dividend and buybacks. The asset-light model (capex ~$9–18M/yr) converts earnings to cash efficiently. For a control buyer, this net-cash, high-FCF profile is exactly what supports a levered private structure.

7. Capital Allocation

Verdict: competent, shareholder-friendly capital return (steady buybacks + a stable ~$1.56 dividend) alongside a disciplined, small-bolt-on M&A pivot into higher-fee niches — a solid B, now moot as the company is private and both returns are suspended.

Pre-take-private, JHG’s capital allocation was straightforward and reasonable for a cash-generative, low-growth manager:

• Share buybacks. Share count fell steadily from 179M (2020) → 154M (2025), roughly −3%/year — a genuine per-share tailwind funded by free cash flow, and more disciplined than peers (e.g., Franklin, whose count rose on stock-funded M&A). Buybacks were suspended in December 2025 under the merger agreement covenants.
• Dividend. A stable ~$1.56/share dividend (~$249M/yr, ~3% yield, ~40% payout on adjusted EPS) — held flat rather than grown, appropriate for a no-organic-growth base, and also suspended after the December-2025 signing. Note the 2020-era payout ratios above 100% reflected the depressed earnings of that year, not an unsustainable policy.
• M&A — a disciplined, coherent pivot, not empire-building. The deals of 2024–2026 were small bolt-ons targeting the surviving niches: Tabula (European ETF platform, 2024), NBK Capital Partners (EM private credit, 100%, 2024), Victory Park Capital (private credit, majority stake acquired Oct 2, 2024 for ~$166M net consideration in cash + stock + earnout; CNO took a strategic VPC minority in Sep 2025 with ≥$600M of commitments — this consolidation is the source of the 2025 revenue gross-up and the NCI jump to ~$1B, most of which is third-party fund capital, not JHG economics), Rantum Capital (DACH private debt/PE, ~€1.2B AUM, 2026) and RBA/Ruffer-style macro multi-asset (~$20B, 2026). Total spend was modest relative to the ~$0.7B annual FCF and the net-cash balance sheet; the strategic logic (diversify into higher-fee, faster-growing private markets and ETFs) is sound, though the deals are too recent to judge on realized returns.

Insider alignment and the Trian factor. The defining governance fact is Trian’s presence: a 20.6% holder since 2020 with board representation, an activist that pushed for strategic change and ultimately led the buyout, rolling 25,136,205 shares into the acquisition vehicle (Jupiter Topco LLC) — the clearest possible alignment/endgame signal. The insider Form 4 record contains zero code-P open-market purchases across 2024–2026; insider activity was routine grants/vests and, at close, deal-driven settlement — the July-2, 2026 Form-4 cluster is entirely merger mechanics, not conviction: unvested RSUs converted to Replacement RSU awards in Topco, unvested PSUs deemed earned at 120% of target and converted to replacement cash/Topco awards, and officers/directors cashed remaining shares at $52.00. In short, management realized its equity at the deal price and rolled forward under private ownership — aligned with the consortium, not with former public holders. Compensation historically emphasized adjusted operating metrics, AUM/flows and relative TSR; the incentive structure is now private.

The capital-allocation record does not carry a red flag — no value-destructive mega-deal, no reckless leverage, no dilutive issuance spree — but nor is it the record of a compounder; it is the sensible stewardship of a cash cow in secular decline, which is exactly the profile that attracts a control buyer.

8. Changes and Headwinds — Last Two Years

Verdict: the dominant “change” is the take-private itself; underneath it, a genuine strategic repositioning that improved the optics without resolving the structural core problem.

• The take-private (dominant event). Trian (20.6%) + General Catalyst nonbinding proposal (late Oct 2025) → definitive $49.00 deal (Dec 22, 2025, 18% premium) → raised to $52.00 (25% premium) → 99.7% shareholder approval (Apr 16, 2026) → regulatory + client consents (Jun 18) → completion and NYSE delisting (Jun 30, 2026). Consortium: Trian (rolled), General Catalyst, QIA, Sun Hung Kai, Lunate; MassMutual and others as backers; debt financing committed by JPMorgan, Citi, BofA, Jefferies, MUFG. Dividend and buybacks suspended from signing.
• Leadership. Ali Dibadj (ex-AllianceBernstein) became CEO in March 2022 and drove the “three pillars” strategy; he continues under private ownership.
• The Guardian Life partnership (April 2025). JHG became Guardian’s investment-grade public fixed-income manager (~$45B general account; ~$46.5B recognized), with Guardian committing up to ~$400M of seed capital and receiving equity warrants — the anchor of the insurance/private-credit build and the driver of both the 2025 flow surge and the FI fee-rate compression.
• The M&A wave (Tabula, NBK, VPC, Rantum, RBA) — the diversification into ETFs and private markets.
• The active-ETF scale-up — JAAA to ~$25B and a top-3 active-FI-ETF franchise.
• Headwinds that persist: accelerating active-equity outflows (−$14B in 2025), blended fee-rate compression (48.9→45.2 bps), mediocre active-equity investment performance, the market-beta sensitivity of the fee base, and the secular passive tide.

Sector read-through (important). A 20.6% activist that engaged for five years concluding that a cash sale to private capital beats standalone public compounding is a bearish structural signal for subscale public active managers generally — a marker that the public market is no longer willing to pay for the standalone active-management business model at scale, and that private/permanent capital sees more value in owning these cash flows outright and levering the private-markets/ETF optionality. Watch the peer set (IVZ, AB, BEN, AMG-affiliates) for similar pressure.

9. Risk Analysis (Risk Matrix)

Because the transaction has closed, the traditional forward equity risks are now the buyers’ risks, not a public shareholder’s. The matrix below frames the risks to the asset and the deal thesis (relevant to peers and to any read-through), plus the residual public-holder considerations.

Catastrophic-loss risk for former public holders is nil — they received cash. The real forward risk now sits with the consortium, whose return depends on out-growing the secular decline with the private-markets/ETF pivot while servicing acquisition leverage.

10. Valuation Discussion — Was $52 Fair?

Because the equity no longer trades, the valuation question is not “what is it worth?” but “was the $52.00 clearing price fair — and to whom?” The analysis cuts three ways: multiples, premium, and the asymmetry between sellers and buyers.

What the buyers paid (at $52.00 / ~$7.4B equity value):

• ~10.9x FY2025 adjusted diluted EPS of $4.78 — but that number is flattered by the lumpy ~$423M performance fee; on the normalized low-$4s run-rate, the multiple is ~12–13x.
• ~7x EV/EBITDA (EV ~$7.0B on ~$1.0B adjusted EBITDA) — a mid-single-digit-to-high-single-digit multiple typical of the sector.
• ~1.5% of AUM ($7.4B / ~$490B) — reasonable-to-cheap versus the ~1–3% range traditional managers command, reflecting the low-fee Guardian mix.
• ~3% dividend yield (on the pre-suspension $1.56) and a ~3% buyback yield — a ~6% pre-deal shareholder-return profile, now redirected to the buyers’ return.

The premium: $52.00 was a 25% premium to the undisturbed ~$41.60 (Oct 24, 2025). The merger agreement was signed December 21, 2025 at $49.00 (18% premium) and amended March 24, 2026 to $52.00 (25%) — the special committee extracting a ~6% bump. A 25% control premium is squarely in the normal range for a negotiated take-private — neither a lowball nor a knockout.

Own-history and peer context — this is where “full” comes from. The deal was struck at JHG’s richest-ever price-to-book (~1.51x stated, 98th own-history percentile), into an AM tape where the entire traditional group had re-rated to decade-high own-history multiples (Franklin at the 99.7th P/B percentile, AllianceBernstein 94.6th, AMG 99.7th). In other words, the 25% premium was paid on top of a peak multiple in a peak sector tape — which is why the fair read is “full-to-generous for sellers,” not “cheap.”

Embedded expectations for the buyers. At ~13x normalized adjusted EPS with a ~6% base cash-return profile and net cash, the consortium needs only modest per-share earnings growth (low-to-mid single digits) plus its private-markets/ETF optionality to earn an acceptable return — provided the active-equity core does not melt faster than the ETF/private-credit build compounds, and provided a market drawdown doesn’t gut the fee base. That is a reasonable private-equity underwrite with a real margin of safety in the balance sheet, but it is not a screaming bargain; the buyers are paying a market-clearing price for a decent-not-great business plus optionality they believe they can accelerate privately.

A simple scenario cross-check. Frame the buyers’ return crudely. Entry EV ~$7.0B against ~$1.0B of adjusted EBITDA (~7x). In a base case, markets rise mid-single-digits annually, the ETF/private-credit build roughly offsets the legacy melt so organic AUM is flat-to-slightly-positive, the fee rate drifts down a touch, and EBITDA compounds ~4–6%/yr; with modest leverage and ~$0.7B/yr of free cash flow to de-gear or reinvest, that is a low-double-digit equity IRR — acceptable for a control buyer. In a bull case, the private-markets book scales its ~80 bps fees, active ETFs keep compounding 30%+, and a re-accelerating tape lifts both AUM and performance fees — EBITDA compounds high-single-to-low-double digits and the IRR is genuinely attractive, especially levered. In a bear case, a 2022-style 25–35% market drawdown cuts the fee base, the legacy equity outflows persist, performance fees normalize toward zero, and acquisition leverage bites — EBITDA falls and the equity return goes negative for a period. The distribution is asymmetric toward the buyers’ favor only if markets cooperate and the pivot scales; the net-cash-at-entry balance sheet is the cushion that keeps the bear case survivable rather than ruinous. That profile — acceptable base, attractive bull, survivable bear — is exactly why a patient, permanent-capital consortium (Trian rolling, QIA and a sovereign/insurance backer base) is the natural owner, and a quarterly-scrutinized public market is not.

Peer comparison (mid-2026):

The table makes the point: JHG was not an outlier-cheap asset the buyers stole — it sat within a sector that had broadly re-rated to expensive own-history levels (its P/B at the 98th percentile of its own decade), and the take-private simply crystallized a full price for public holders while handing the forward risk/reward to private capital. If anything, JHG’s ~1.6% of AUM is cheap versus strategic AM M&A (typically 2–3% of AUM), which is why the read tilts fair-to-slightly-buyer-favorable rather than generous-to-buyers. No price target and no recommendation attach to this analysis; the security no longer exists.

11. Variant Perception

Consensus (at the time of the deal): JHG was a successful turnaround — six straight quarters of inflows, record AUM, expanding margins, a credible ETF/private-markets pivot — and $52 was a fair-to-slightly-light price that Trian, knowing the asset best, was happy to pay/roll into.

The strongest bull case (the buyers’ case): You are acquiring, at ~13x normalized earnings and ~1.5% of AUM, a net-cash, high-FCF, asset-light franchise with a genuine first-mover active-ETF/CLO business (JAAA ~$25B), strong FI/multi-asset/alts performance, a sticky insurance anchor (Guardian), and a private-credit platform — all of which compound better under patient private capital, with AI/technology operating leverage, than under quarterly public-flow scrutiny. Lever the balance sheet modestly, keep the management team, accelerate the private-markets build, and the equity IRR is attractive even with a melting legacy equity book.

The strongest bear case (the sellers were right to take cash): You are paying a peak multiple in a peak tape for a business whose highest-fee core is in accelerating decline (−$14B equity outflows), whose fee rate is compressing, whose 2025 earnings are one-time-flattered, and which has no structural barrier against passive. The “growth” is one low-fee insurance mandate and market beta. A market drawdown (β~1.3) would cut the fee base hard, and the private-markets pivot is early and unproven on realized returns. The activist who knew it best chose to sell the whole thing for cash rather than compound it — the most eloquent bear argument there is.

The 3–5 assumptions that mattered most:

1. Whether the active-equity core stabilizes or keeps melting (bear: keeps melting).
2. Whether the active-ETF/private-credit build can out-compound the legacy decline (bull’s whole case).
3. Whether FY2025’s earnings are a run-rate or a one-time peak (evidence: substantially one-time).
4. Whether the Guardian-style low-fee growth is a feature or a margin trap (both).
5. Whether markets cooperate (β~1.3 makes this exogenous and decisive).

What would have falsified each side: Bull falsified if organic, ex-Guardian, ex-lumpy-fee active flows and earnings had failed to grow post-deal — which the pre-deal trend already suggested. Bear falsified if the ETF/private-credit franchise had reached a scale where it more than offset the legacy melt on an organic basis — which it had not yet done at the time of the sale. The factor tape corroborates the bear’s structural read: JHG carried a strongly negative Growth loading (−0.45) and negative Quality (−0.09) with positive Value/Dividend tilts — the statistical fingerprint of a cheap, low-growth, market-sensitive financial, not a quality compounder, which is exactly the kind of asset that ends up bought for cash rather than re-rated on fundamentals.

12. Fact vs. Interpretation

13. Open Questions

1. Normalized run-rate earnings: what is FY2026 adjusted EPS ex-the-2025-lumpy-performance-fee and ex-VPC-NCI-gross-up — i.e., the true earnings base the buyers underwrote? (Now visible only in private financials.)
2. Post-deal capital structure: how much acquisition leverage did the consortium place on the (previously net-cash) balance sheet, and at what rate?
3. Guardian economics: the precise fee schedule, duration, warrant terms and renewal risk of the ~$45–50B insurance capital.
4. Active-equity trajectory: has the −$14B/yr equity outflow stabilized post-deal, or is the legacy core melting faster than the ETF/private-credit build compounds?
5. Realized M&A returns: how are VPC, NBK, Rantum and RBA performing against the earnouts and the diversification thesis?
6. Insider Form 4 / proxy detail: the exact management economics at close and the compensation/incentive structure under private ownership (SEC-sweep workstream).

14. What Must Be True

For the buyers’ underwrite to work (bull):

1. The active-ETF and private-credit franchises out-compound the legacy active-equity decline on an organic basis within a few years. Falsification: organic ex-Guardian flows turn negative again, or JAAA/ETF growth stalls as competitors scale CLO ETFs.
2. Markets cooperate enough (no sustained drawdown) that the β~1.3 fee base holds while the pivot matures. Falsification: a 2022-style bear market cuts AUM 25–35% and craters the fee base under new leverage.
3. Normalized earnings (~$4.00) grow low-to-mid single digits and the private-markets book scales its higher fees. Falsification: FY26–27 normalized earnings step down and stay down as the lumpy 2025 fee doesn’t repeat and equity outflows persist.

For the sellers to have been right to take cash (bear):

1. The core active-equity business keeps melting and fee compression continues, so standalone public value would have stagnated. Falsification: equity flows and fee rate stabilize post-deal — evidence the public market mispriced a real inflection.
2. $52 captured a peak multiple in a peak tape that would not have persisted through the next market cycle. Falsification: the AM group holds its re-rated multiples and JHG-comparable peers compound from here.
3. The activist’s decision to sell rather than compound correctly judged that private capital could extract more value than public markets would pay. Falsification: the consortium struggles to grow the asset and the sale looks, in hindsight, like selling the bottom of a genuine turnaround.

The weight of the pre-deal evidence — accelerating core outflows, one-time-flattered earnings, a compressing fee rate, and a five-year activist choosing cash — favors the bear/seller framing: $52 was a fair-to-full price to exit, and the burden now sits with the buyers to prove the private-markets reinvention can outrun the secular tide.

15. Source Appendix

See the Source Appendix below for the full source list. Primary sources: Janus Henderson SEC filings (10-K, 10-Q, 8-K earnings releases, DEF 14A/merger proxy, Form 4) via EDGAR (CIK 0001274173); company press releases on the take-private (Dec 2025 announcement, Apr 2026 shareholder approval, Jun 2026 completion); Q3 2025 and Q4/FY2025 earnings calls and releases; third-party financial databases for computed statements/ratios/EV (reconciled to filings), own-history valuation percentiles, price data, and factor-model estimates. Peer data from public filings.

APPENDIX A — Standard Diligence Questionnaire

Supplemental to the research memo. As-of July 11, 2026. Note: JHG was taken private and delisted on June 30, 2026 at $52.00/share; answers below describe the asset as it stood at the transaction, and the deal itself where relevant.

General

What thoughtful questions have other investors asked about this company? The dominant questions were (1) whether the flow “turnaround” was real and organic or an artifact of one insurance mandate plus market beta; (2) whether the improving adjusted margin was structural or performance-fee-driven; (3) what Trian (20.6%, on the board since 2020/2022) would ultimately do — engage, sell down, or take it out; and (4) whether a subscale active manager could out-run the secular passive tide by pivoting to ETFs and private credit. The last question was answered on December 21, 2025, when Trian and General Catalyst agreed to take the company private for $49.00 (later $52.00) per share — i.e., the informed insider chose a cash sale over standalone compounding.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? A cyclical high, and flattered. FY2025 adjusted EPS of $4.78 embeds a lumpy ~$423M hedge-fund performance-fee crystallization (total performance fees leapt from ~$70M in 2024 to ~$460M in 2025) and elevated seed/CIP investment gains in a strong tape; the normalized run-rate is in the low-$4s. AUM was at a record ~$493B on strong markets.

Driven by external environment or internal actions? Predominantly external — fee revenue accrues on market-linked AUM (β~1.3), and 2025’s flow surge was one Guardian mandate plus ~$50B of market appreciation. Internal actions (cost discipline, ETF/private-credit build) helped the margin and mix but did not drive the headline.

How stable are revenues? Moderately unstable — market-sensitive and flow-sensitive. The 2022 bear market cut AUM ~34%; performance fees are lumpy.

Outlook for products/services? The legacy active-equity core is in secular decline (accelerating outflows); the active-ETF and private-credit/insurance franchises are growing. Net: reinvention-dependent.

How big is this market — growing or shrinking? The active-management profit pool is shrinking in aggregate (passive share gains, fee compression), with growing sub-pools in active ETFs and private markets. Global, with JHG ~67% North America.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More — passive substitution, fee wars, and consolidation intensify competition for a shrinking active pool.

How profitable is the business (ROIC, ROE)? Adjusted operating margin ~36% (FY25), ROIC ~12.6%, normalized ROE ~14–15% — a decent asset-light return modestly above cost of capital. Reported ROE of ~53% is a one-time-flattered mirage.

How profitable is the industry / barriers to entry? Low structural barriers; some customer captivity (distribution shelf, advisor inertia, ETF/insurance stickiness) and distribution scale economies, but no durable barrier against passive. Narrow-to-no moat.

Can the business be easily understood? Yes — assets × fee rate, minus costs; the complications are the consolidated-VIE gross-up and performance-fee lumpiness.

Can it be undermined by foreign low-cost labor? Not materially; it is undermined by passive/technology, not offshoring.

Do brands matter? Somewhat — Janus Henderson and product brands (JAAA) carry distribution weight, but brand does not confer pricing power against passive.

Nature of competition / switching costs? Performance and price competition; switching costs are low for retail performance-chasers, higher for institutional/insurance mandates and ETF positions.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The investment track records, distribution relationships and the Guardian/insurance franchise are intangible value not fully on the books; conversely, ~$4.15B of goodwill/intangibles overstate tangible equity (TCE only ~$0.96B).

Off-balance-sheet liabilities? None material. The consolidated VIEs (VPC funds/CLOs, seed products) inflate gross assets and NCI but are largely non-recourse third-party capital.

How conservative is the accounting? Reasonable, but 2025 GAAP is noisy — GAAP exceeded adjusted on non-recurring gains; the consolidated-VIE gross-up and lumpy performance fees require normalization. Read adjusted, net of NCI.

How CapEx-hungry? Negligible — capex ~$9–18M/yr; asset-light; ~$0.7B/yr FCF.

Capital Allocation & Management

How much FCF, and how used? ~$0.7B/yr; historically ~40% to a stable ~$1.56 dividend, the balance to steady buybacks (share count 179M→154M, ~2.5%/yr net of SBC). Both suspended at the December-2025 deal signing.

Significant acquisitions recently? Yes — a disciplined bolt-on pivot: Tabula (2024), NBK Capital Partners (2024), Victory Park Capital (majority, Oct 2024, ~$166M), Rantum (2026), RBA (2026). Small relative to FCF; capability-driven.

Buying back shares / issuing to insiders? Net buyer of ~2.5%/yr pre-deal; SBC ~$80M/yr; no large dilutive issuance. At close, insider equity was cashed/rolled at $52 (PSUs deemed at 120% of target).

Compensation / incentive alignment? Historically adjusted operating metrics, AUM/flows and relative TSR; Trian’s 20.6% stake and board seats were the dominant alignment force, culminating in the buyout. Zero insider open-market purchases (code P) 2024–2026.

Motivations of management? Post-buyout, aligned with the consortium (equity rolled into Topco); Dibadj continues as CEO with a private-ownership mandate to build “the most technologically sophisticated asset manager in the world.”

Valuation & Market Data

ADR / MLP / K-1? No — JHG was an ordinary-share NYSE listing (Jersey-incorporated plc, U.S. domestic SEC filer). Not an MLP/K-1 issuer.

Dividend policy? ~$1.56/share, ~3% yield, ~40% adjusted payout, flat (no growth, no cut historically); suspended at deal signing.

How profitable is the business? See above — ~36% adjusted operating margin, ~12.6% ROIC.

Net income vs cash from operations diverging? In 2025, GAAP net income was inflated by non-cash/non-recurring gains; cash from operations (~$0.72B) is the cleaner read and tracks adjusted earnings, not the GAAP spike.

Risks & Downside

What would cause the stock to decline? (Now moot — cash deal closed.) Pre-deal: a market drawdown (β~1.3), accelerating core outflows, performance-fee normalization, or deal failure. For the buyers: the legacy melt outrunning the pivot, plus acquisition leverage.

Risk of catastrophic loss? For former public holders, nil — they received cash. Forward catastrophic risk sits with the levered private consortium in a severe, sustained market decline.

Chance of total loss? None for former holders (cash). For the buyers, a total loss is implausible given the net-cash-at-acquisition franchise and ~$0.7B FCF, absent extreme leverage plus a prolonged bear market.

Recent News & Events

Has the business environment changed recently? Decisively — the take-private closed June 30, 2026 and the shares delisted. Underneath: the Guardian mandate (Apr 2025), the M&A wave, the JAAA-led active-ETF scale-up, and Dibadj’s restructuring.

Significant acquisitions? VPC/NBK/Tabula/Rantum/RBA (above); JHG itself was the ultimate acquisition target.

Change in accounting policies? None material beyond the consolidation of VPC as a VIE (revenue/NCI gross-up).

Recent changes — new markets, facilities, management? Expansion into European ETFs (Tabula), EM/DACH private credit (NBK/Rantum), insurance solutions (Guardian/CNO); management continuity under Dibadj; ownership change to a private consortium.

APPENDIX B — Source Appendix

As-of July 11, 2026. Facts labeled FACT in the memo trace to these sources. Fact = primary disclosure; Interpretation = independent analysis built on it.

Corporate / Transaction (take-private)

• Janus Henderson press release — “Janus Henderson Group plc to be Acquired by Trian Fund Management and General Catalyst for $7.4 Billion” (Dec 22, 2025; merger agreement signed Dec 21, 2025): $49.00/share, 18% premium to undisturbed $41.60 (Oct 24, 2025); Trian rolls its 20.6% stake; consortium incl. QIA, Sun Hung Kai, MassMutual; debt financing committed by JPMorgan, Citi, BofA, Jefferies, MUFG. https://www.janushenderson.com/corporate/press-releases/janus-henderson-group-plc-to-be-acquired-by-trian-fund-management-and-general-catalyst-for-7-4-billion/
• Merger agreement amendment to $52.00/share (25% premium), dated March 24, 2026 (per merger proxy / 8-K).
• Janus Henderson press release — “Resounding Shareholder Approval” (Apr 16, 2026): 99.7% of votes cast in favor at the EGM. https://www.businesswire.com/news/home/20260416407092/en/
• Janus Henderson press release — regulatory approvals and client consents (Jun 18, 2026). https://www.businesswire.com/news/home/20260618929995/en/
• Janus Henderson press release — “Completes Take-Private Transaction with Trian, General Catalyst, and QIA” (Jun 30, 2026): $52.00/share cash; NYSE delisting; consortium incl. Sun Hung Kai, Lunate; Dibadj continues as CEO; London + Denver bases. https://www.janushenderson.com/corporate/press-releases/janus-henderson-completes-take-private-transaction-with-trian-general-catalyst-and-qia/
• SEC EDGAR — Janus Henderson filings index, CIK 0001274173 (10-K, 10-Q, 8-K, DEF 14A/merger proxy, Form 3/4/5, Schedule 13D/13G). Form-4 cluster dated Jul 2, 2026 = merger-settlement conversions/dispositions (Replacement RSUs in Jupiter Topco LLC; PSUs at 120% of target; Trian rollover of 25,136,205 shares). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001274173

Financial statements / results

• Janus Henderson Q4 & Full-Year 2025 Results (8-K, released Jan 30, 2026): FY25 adjusted diluted EPS $4.78; adjusted operating margin 36.0%; Q4’25 adjusted dil EPS $2.01 / GAAP $2.62; year-end AUM $493.2B. https://ir.janushenderson.com/News--Events/news/news-details/2026/Janus-Henderson-Group-plc-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx
• Janus Henderson Q3 2025 Results & earnings call (Oct 30, 2025): AUM $483.8B (record, +27% YoY); 6th consecutive positive-flow quarter; +7% organic growth; net management fee rate 42.7 bps; adjusted dil EPS $1.09 (+20% YoY); Guardian + CNO ~$50B / ~10% of AUM; JAAA and active-FI-ETF detail; Trian/General Catalyst nonbinding proposal disclosed in CEO remarks. (earnings-call transcript; ir.janushenderson.com)
• Janus Henderson 10-K (FY2025) and prior 10-Ks/10-Qs (2021–2025), EDGAR corpus mirrored locally — AUM by asset class/channel/geography, net flows by capability, fee rates, VPC/CNO consolidation, debt (2034 notes), buyback authorization, dividend history.
• Third-party financial database — computed income statement, balance sheet, cash flow, profitability/valuation ratios and enterprise value (FY2020–2025), reconciled to filings: revenue $2,767M/$2,204M/$2,102M/$2,473M/$3,097M (2021–25); GAAP dil EPS; ROIC 12.6% (2025); EV ~$5.9B; net cash ~$0.9B; FCF ~$0.71B (2025). Third-party aggregated; filings are primary.

Flows / AUM / fee-rate detail (from filings + IR)

• Net long-term flows: −$0.7B (2023), +$2.4B (2024), +$56.5B (2025); ~$46.5B Guardian; equity-capability flows −$2.2B/−$6.5B/−$14.0B (2023–25).
• Blended net management fee rate 48.9 → 48.6 → 45.2 bps (2023–25); fixed income to ~19.8 bps; equities ~53–54 bps; alternatives ~82 bps.
• Performance fees ~$5M (2023) → ~$70M (2024) → ~$460M (2025), incl. ~$423M lumpy hedge-fund crystallization.
• Investment performance (% AUM beating benchmark, 1/3/5/10yr, 12/31/25): Equities 55/46/48/54; Fixed Income 68/93/90/92; Multi-Asset 96/96/98/97; Alternatives ~100.

Guardian / M&A

• Guardian Life strategic partnership (announced Apr 8, 2025): JHG becomes Guardian’s IG public fixed-income manager (~$45B general account; ~$46.5B recognized in flows); Guardian commits up to ~$400M seed capital and receives equity warrants/economic consideration. (Company press release / 10-K)
• Victory Park Capital — majority stake acquired Oct 2, 2024 (~$166M net consideration); CNO strategic VPC minority (Sep 24, 2025, ≥$600M commitments); consolidated as a VIE. NBK Capital Partners (EM private credit, 100%, 2024). Tabula (European ETF platform, 2024). Rantum Capital (DACH private debt/PE, ~€1.2B, 2026). RBA macro multi-asset (~$20B, 2026). (Company press releases / 10-K)
• Active-ETF franchise: JAAA (pioneer AAA-CLO ETF) ~$5.3B (early 2024) → ~$16.6B (end 2024) → ~$25B (2026); JHG top-3 active fixed-income ETF and top-8 active-ETF issuer. (IR / third-party ETF data)

Market / factor / price data

• Adjusted price history (third-party market data) — 5yr low $16.87 (Oct 11, 2022), 5yr/52-wk high $53.21 (Feb 26, 2026), last trade $51.95 (Jun 30, 2026); beta ~1.21–1.38.
• Own-history valuation percentiles (third-party data, 6/30/26): P/E 49.7th (10.25x trailing GAAP), P/B 98.0th (1.51x, richest-ever), P/S 78.2nd (2.49x), composite 75.3rd.
• Factor-model estimates (third-party, 6/30/26): Market beta 1.38; Growth −0.45, Quality −0.09, Value +0.15, DividendYield +0.15, Momentum −0.07; y1 return +36% (Sharpe 1.6); y5 +10.8% ann (max drawdown −57%); R² 0.63.
• Peers (mid-2026, third-party market data): TROW P/E 10.8x / EV-EBITDA 6.7x / P/B 2.06x (36th pctile); AB 13.0x / P/B 3.04x (95th); BEN 22.8x depressed / P/B 1.03–1.43x (99.7th); IVZ neg. GAAP / P/B 1.98x; AMG 15.2x / P/B 3.26x (99.7th). Cross-read from public peer filings and disclosures.

Note: third-party aggregated market and factor data is used only as a cross-check, reconciled to primary filings; where any disagreed with the 10-K/8-K, the filing governs.